Skip to main content
SpringerLink
Log in

Oral administration of coenzyme Q10 reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice

  • Brief Communication
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The neuroprotective effect of coenzyme Q10 (CoQ10) has been reported in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. In this study, we investigated whether oral administration of CoQ10 could protect the striatal dopaminergic (DAergic) nerve terminals against MPTP-induced toxicity in C57BL/6N mice using immunoisolation technique for DAergic synaptosomes. CoQ10 significantly attenuated decrease in dopamine transporter as well as in synaptophysin and actin protein levels in DAergic synaptosomes from MPTP-treated mice. The effect of CoQ10 was also observed in crude synaptosomes fraction, but not in homogenate. Our results indicate that the nerve terminals are a site for the action of CoQ10 against the MPTP-induced DAergic neurodegeneration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163:1450–1455

    Article  PubMed  CAS  Google Scholar 

  2. Parker WD Jr, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 26:719–723

    Article  PubMed  Google Scholar 

  3. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269

    Article  PubMed  CAS  Google Scholar 

  4. Hattori N, Tanaka M, Ozawa T, Mizuno Y (1991) Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson’s disease. Ann Neurol 30:563–571

    Article  PubMed  CAS  Google Scholar 

  5. Crane FL (2001) Biochemical functions of coenzyme Q10. J Am Coll Nutr 20:591–598

    PubMed  CAS  Google Scholar 

  6. Moon Y, Lee KH, Park JH, Geum D, Kim K (2005) Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J Neurochem 93:1199–1208

    Article  PubMed  CAS  Google Scholar 

  7. Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S (2005) Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol Dis 18:618–627

    Article  PubMed  CAS  Google Scholar 

  8. Schulz JB, Henshaw DR, Matthews RT, Beal MF (1995) Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol 132:279–283

    Article  PubMed  CAS  Google Scholar 

  9. Beal MF, Matthews RT, Tieleman A, Shults CW (1998) Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783:109–114

    Article  PubMed  CAS  Google Scholar 

  10. Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF (2008) Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of parkinsonism. J Neurochem 104:1613–1621

    Article  PubMed  CAS  Google Scholar 

  11. Beal MF (1999) Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors 9:261–266

    Article  PubMed  CAS  Google Scholar 

  12. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M, Parkinson Study Group (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541–1550

    Article  PubMed  Google Scholar 

  13. Mitsumoto Y, Watanabe A, Mori A, Koga N (1998) Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem Biophys Res Commun 248:660–663

    Article  PubMed  CAS  Google Scholar 

  14. Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909

    Article  PubMed  CAS  Google Scholar 

  15. Nakai M, Mori A, Watanabe A, Mitsumoto Y (2003) 1-methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Δψm) in rat striatum. Exp Neurol 179:103–110

    Article  PubMed  CAS  Google Scholar 

  16. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res 134:57–66

    Article  PubMed  CAS  Google Scholar 

  17. Sriram K, Pai KS, Boyd MR, Ravindranath V (1997) Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res 749:44–52

    Article  PubMed  CAS  Google Scholar 

  18. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Członkowski A, Członkowska A (1998) Microglial and astrocytic involvement in a murine model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39:167–180

    Article  PubMed  CAS  Google Scholar 

  19. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4:600–609

    Article  PubMed  CAS  Google Scholar 

  20. Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, Bezard E (2003) Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson’s disease. Mol Neurobiol 28:209–218

    Article  PubMed  CAS  Google Scholar 

  21. Hasbani DM, O’Malley KL (2006) Wlds mice are protected against the parkinsonian mimetic MPTP. Exp Neurol 202:93–99

    Article  PubMed  CAS  Google Scholar 

  22. Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, Di Monte DA, Macarthur H, Andersen JK (2008) MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS One 3:e1616

    Article  PubMed  Google Scholar 

  23. Muroyama A, Kobayashi S, Mitsumoto Y (2011) Loss of striatal dopaminergic terminals during the early stage in response to MPTP injection in C57BL/6 mice. Neurosci Res 69:352–355

    Article  PubMed  CAS  Google Scholar 

  24. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1996) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16:436–447

    PubMed  CAS  Google Scholar 

  25. Li LH, Qin HZ, Wang JL, Wang J, Wang XL, Gao GD (2009) Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Int Med Res 37:455–463

    PubMed  CAS  Google Scholar 

  26. Sievers C, Platt N, Perry VH, Coleman MP, Conforti L (2003) Neurites undergoing Wallerian degeneration show an apoptotic-like process with Annexin V positive staining and loss of mitochondrial membrane potential. Neurosci Res 46:161–169

    Article  PubMed  CAS  Google Scholar 

  27. Ikegami K, Koike T (2003) Non-apoptotic neurite degeneration in apoptotic neuronal death: pivotal role of mitochondrial function in neurites. Neuroscience 122:617–626

    Article  PubMed  CAS  Google Scholar 

  28. Mitsumoto Y, Kobayashi S, Matsushima H, Muroyama A, Yoshimura I (2009) Oral administration of coenzyme Q10 prevents cytochrome c release from mitochondria induced by 1-methyl-4-phenylpyridinium ion in mouse brain synaptosomes. Neurosci Lett 463:22–25

    Article  PubMed  CAS  Google Scholar 

  29. Sagot Y, Dubois-Dauphin M, Tan SA, de Bilbao F, Aebischer P, Martinou JC, Kato AC (1995) Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. J Neurosci 15:7727–7733

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Specific Research Fund of the Hokuriku University.

Author information

Authors and Affiliations

  1. Department of Alternative Medicine and Experimental Therapeutics, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Ishikawa, 920-1181, Japan

    Shota Kobayashi, Akiko Muroyama & Yasuhide Mitsumoto

  2. Research Institute, Fujimoto Pharmaceutical Corp., Matsubara, Osaka, 580-8053, Japan

    Hiroaki Matsushima

  3. Nisshin Pharma Inc., Tokyo, 101-8441, Japan

    Ikuo Yoshimura

Authors
  1. Shota Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akiko Muroyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroaki Matsushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ikuo Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuhide Mitsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuhide Mitsumoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kobayashi, S., Muroyama, A., Matsushima, H. et al. Oral administration of coenzyme Q10 reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice. Neurol Sci 33, 195–199 (2012). https://doi.org/10.1007/s10072-011-0627-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-011-0627-z

Keywords

Search

Navigation